No Data
No Data
Outlook Therapeutics(R) (NASDAQ:OTLK) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
Watch the "What This Means" video hereOutlook CEO, Russ Trenary underscores that LYTENAVA (bevacizumab gamma) has become the first ophthalmic formulation of bevacizumab to receive European Commission
Buy Rating Justified by Outlook Therapeutics' Advancements and Market Prospects
Express News | Outlook Therapeutics Gains Marketing Authorization From European Commission For LYTENAVA To Treat Retina Diseases
Express News | Outlook Therapeutics Inc - Strategic Partnership With Cencora (Formerly Amerisourcebergen) to Support Planned Commercial Launches of Lytenava in EU
Express News | Outlook Therapeutics Inc - Lytenava™ (Bevacizumab Gamma) Receives Ten Years of Market Exclusivity in EU
Express News | Outlook Therapeutics Inc - Advancing Toward Commercial Launch of Lytenava™ (Bevacizumab Gamma) in EU Expected in Calendar Q1 2025
No Data